2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 924

Patient and Provider Factors in Optimal Gout Management
Abstract Number: 925

Musculoskeletal Ultrasound (MSK-US): Innovation or Overutilization?
Abstract Number: 926

Development of an Ultrasound Joint Inflammation Score for Rheumatoid Arthritis through a Data-Driven Approach
Abstract Number: 927

Ultrasound Assessment of Heel Entheses in Spondyloarthritis Patients: A Comparative Study with Radiography and Magnetic Resonance Imaging
Abstract Number: 928

The Value of Early Ultrasound-Detected Osteophytes in Hand Osteoarthritis: Predicting the Future
Abstract Number: 929

Diurnal Variation of Power Doppler in Metacarpophalangeal Joints of Patients with Rheumatoid Arthritis
Abstract Number: 930

Evaluation of Temporomandibular Joint Arthritis with Ultrasound in Juvenile Idiopathic Arthritis
Abstract Number: 931

mTOR Complex 1 Signaling Is Required for the Steady-State in Vivo Development of Inflammatory Monocytes
Abstract Number: 932

IRF4-Dependent and IRF4-Independent Pathways Contribute to DC Dysfunction in Lupus
Abstract Number: 933

DEK-Targeting DNA Aptamers As Novel Therapeutics for Inflammatory Arthritis
Abstract Number: 934

Platelet-Independent Role of Megakaryocytes in Antibody-Mediated Murine Arthritis
Abstract Number: 935

Microrna-146a Provides Feedback Regulation of Monosodium Urate-Induced Gouty Arthritis in Mice By Targeting Tumor Necrosis Factor Receptor Associated Factor 6 and Interleukin-1 Receptor-Associated Kinase 1
Abstract Number: 936

IL-1 Receptor Antagonist Maintains Intestinal Microbial Homeostasis to Prevent Overt Toll-like Receptor 4-Dependent Intestinal Th17 Differentiation and Autoimmune Arthritis
Abstract Number: 937

Safety and Efficacy of Canakinumab in Patients with CAPS: Interim Results from the Beta-Confident Registry
Abstract Number: 938

Long-Term Efficacy and Safety of Canakinumab in Patients with Active Recurrent or Chronic TNF Receptor-Associated Periodic Syndrome

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].